Metabolic profile of indapamide sustained-release in patients with hypertension: Data from three randomised double-blind studies

Drug Safety

Volumn 24, Issue 15, 2001, Pages 1155-1165

  Weidmann, Peter ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b Hospital Europa   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INDAPAMIDE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE PREPARATION; URIC ACID BLOOD LEVEL;

EID: 0035714450     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200124150-00006     Document Type: Article

References (45)

1. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study
2. Stratifying the patient at risk from coronary disease: New insights from the Framingham Heart Study
3. Long-term epidemiologic prediction of coronary disease. The Framingham experience
4. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI)
5. International Society of Hypertension guidelines for the management of hypertension
6. MRC Working Party search Council trial of treatment of hypertension in older adults: Principal results
7. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP)
8. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context
9. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension)
10. Adverse metabolic effects of antihypertensive drugs: Implications for treatment
11. Antihypertensive agents, serum lipoproteins and glucose metabolism
12. The effects of antihypertensive drugs on serum lipids and lipoproteins, I: Diuretics
13. Glucose intolerance in hypertensive patients treated with diuretics, a 14-year follow-up
14. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension
15. Influence of diuretics, calcium antagonists, and α-blockers on insulin sensitivity and glucose tolerance in hypertensive patients
16. Correction of altered noradrenaline reactivity in essential hypertension by indapamide
17. Changes in vascular reactivity in experimental hypertensive animals following treatment with indapamide
18. Pharmacokinetics and metabolism of indapamide: A review
19. Cardiovascular protective properties of indapamide
20. Indapamide: A review of its pharmacodynamic properties and therapeutic efficacy in hypertension
21. Indapamide reduces hypertensive left ventricular hypertrophy: An international multicenter study
22. Effect of indapamide on left ventricular hypertrophy in hypertension: A meta-analysis
23. Long-term effects of indapamide: Final results of a 2-year Italian multicenter study in systemic hypertension
24. Indapamide in the treatment of hypertension in non-insulin-dependent diabetes
25. A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides
26. Arterial hypertension in diabetes
27. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: Results of randomized double-blind controlled studies
28. Twenty-four hour antihypertensive efficacy of indapamide, 1.5-mg sustained release: Results of two randomized double-blind controlled studies
29. Comparison of the haemodynamic and autonomic effects of furosemide and indapamide and localization of the natriuretic action of indapamide
30. Pharmacokinetics of sustainedand immediate- release formulations of indapamide after single and repeated oral administration in healthy volunteers
31. Efficacy and tolerance of indapamide sustained release 1.5 mg on 24-h blood pressure in essential hypertension
32. Centralized echocardiogram quality control in a multicenter study of regression of left ventricular hypertrophy in hypertension
33. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: The LIVE study
34. How left ventricular geometry pattern influences left ventricular hypertrophy regression in hypertensive patients over 1 year: The LIVE study
35. Do different hemodynamic effects of antihypertensive drugs translate into different safety profiles?
36. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly
37. Effect of low dose versus conventional dose thiazide diuretic on insulin action in essential hypertensives
38. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension
39. Thiazide-induced hyperglycaemia: A role for calcium-activated potassium channels?
40. Low and conventional dose cyclo-penthiazide on glucose and lipid metabolism in mild hypertension
41. Relation between dose of bendrofluazide, antihypertensive effect and adverse biochemical effects
42. Tolerability and well-being with indapamide in the treatment of mild-moderate hypertension: An Italian multicenter study
43. Beneficial effects of indapamide on lipoproteins and apoproteins in ambulatory hypertensive patients
44. Requirements for antihypertensive therapy in diabetic patients: Metabolic aspects
45. Antihypertensive therapy in diabetic patients: The use of indapamide